+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Grail Inc - Product Pipeline Analysis, 2021 Update

  • PDF Icon

    Company Profile

  • 36 Pages
  • February 2022
  • GlobalData
  • ID: 4787299
Grail Inc (Grail) is a healthcare company which conducts medical research for developing a blood screening test for early detection of cancer. The company utilizes population-scale clinical trials, data science, high-intensity sequencing and state of art of computer science to understand cancer biology and develop blood tests for early-stage cancer detection. Its area produces data and transforms it into clinically actionable insights to classify patients according to the presence, type, and severity of cancer. Grail’s clinical studies include Circulating cell-free genome atlas study (CCGA), SUMMIT study, and Strive study. The company has an operation with an additional office in Hong Kong. Grail is headquartered in Menlo Park, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Grail Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Grail Inc Company Overview
  • Grail Inc Company Snapshot
  • Grail Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Grail Inc - Pipeline Analysis Overview
  • Grail Inc - Key Facts
  • Grail Inc - Major Products and Services
  • Grail Inc Pipeline Products by Development Stage
  • Grail Inc Ongoing Clinical Trials by Trial Status
  • Grail Inc Pipeline Products Overview
  • Blood-Based Test - Breast Cancer
  • Blood-Based Test - Breast Cancer Product Overview
  • Blood-Based Test - Breast Cancer Clinical Trial
  • Blood-Based Test - Lung Cancer
  • Blood-Based Test - Lung Cancer Product Overview
  • Blood-Based Test - Lung Cancer Clinical Trial
  • Diagnostic Aid For Cancer (DAC) Test
  • Diagnostic Aid For Cancer (DAC) Test Product Overview
  • Galleri - LDT
  • Galleri - LDT Product Overview
  • Galleri - LDT Clinical Trial
  • Minimal Residual Disease Test
  • Minimal Residual Disease Test Product Overview
  • Next Generation Galleri
  • Next Generation Galleri Product Overview
  • Grail Inc - Key Competitors
  • Grail Inc - Key Employees
  • Grail Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Recent Developments
  • Grail Inc, Recent Developments
  • Jul 23, 2021: EC launches probe into Illumina’s proposed acquisition of GRAIL
  • Jun 25, 2021: ESMO: Blood test for early detection of cancer: Final study results support screening use
  • Apr 01, 2021: FTC challenges Illumina’s proposed $7.1bn Grail acquisition
  • Feb 25, 2021: Multi-cancer early detection company GRAIL now hiring for state-of-the-art laboratory facility in Research Triangle Park
  • Jan 11, 2021: GRAIL announces collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate cancer early detection technology for minimal residual disease
  • Sep 22, 2020: Illumina to acquire Grail in a deal worth $8bn
  • Feb 18, 2020: GRAIL initiates first interventional study using its Multi-Cancer Early Detection Test to guide clinical care
  • Jan 21, 2020: Blood-based test could help identify hard-to-detect gastrointestinal cancers
  • Dec 16, 2019: GRAIL appoints Gautam Kollu as Chief Commercial Officer
  • Oct 07, 2019: GRAIL appoints Matthew Young as Chief Operating Officer and Chief Financial Officer

Appendix
  • Methodology
  • About the Publisher
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Grail Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Grail Inc Pipeline Products by Equipment Type
  • Grail Inc Pipeline Products by Indication
  • Grail Inc Ongoing Clinical Trials by Trial Status
  • Grail Inc, Key Facts
  • Grail Inc, Major Products and Services
  • Grail Inc Number of Pipeline Products by Development Stage
  • Grail Inc Pipeline Products Summary by Development Stage
  • Grail Inc Ongoing Clinical Trials by Trial Status
  • Grail Inc Ongoing Clinical Trials Summary
  • Blood-Based Test - Breast Cancer - Product Status
  • Blood-Based Test - Breast Cancer - Product Description
  • Blood-Based Test - Breast Cancer - Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection: The STRIVE Study
  • Blood-Based Test - Lung Cancer - Product Status
  • Blood-Based Test - Lung Cancer - Product Description
  • Blood-Based Test - Lung Cancer - The SUMMIT Study: Cancer Screening Study with or Without Low Dose Lung CT to Validate a Multi-cancer Early Detection Test
  • Diagnostic Aid For Cancer (DAC) Test - Product Status
  • Diagnostic Aid For Cancer (DAC) Test - Product Description
  • Galleri - LDT - Product Status
  • Galleri - LDT - Product Description
  • Galleri - LDT - A Study to Evaluate the Galleri Blood Test in the Multi-cancer Early Detection Test
  • Galleri - LDT - Assessment of the Implementation of an Investigational Multi-cancer Early Detection Test into Clinical Practice: The PATHFINDER Study
  • Galleri - LDT - The Circulating Cell-free Genome Atlas Study
  • Galleri - LDT - The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-cancer Early Detection Test in an Eligible Screening Population
  • Minimal Residual Disease Test - Product Status
  • Minimal Residual Disease Test - Product Description
  • Next Generation Galleri - Product Status
  • Next Generation Galleri - Product Description
  • Grail Inc, Key Employees
  • Grail Inc, Subsidiaries
  • Glossary

List of Figures
  • Grail Inc Pipeline Products by Equipment Type
  • Grail Inc Pipeline Products by Development Stage
  • Grail Inc Ongoing Clinical Trials by Trial Status

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Biocept Inc
  • Sysmex Inostics GmbH
  • ApoCell Inc
  • Circulogene Theranostics Inc